dc.contributor.author | Flygel, Trym Thune | |
dc.contributor.author | Hameiri-Bowen, Dan | |
dc.contributor.author | Simms, Victoria | |
dc.contributor.author | Rowland-Jones, Sarah | |
dc.contributor.author | Ferrand, Rashida Abbas | |
dc.contributor.author | Bandason, Tsitsi | |
dc.contributor.author | Yindom, Louis-Marie | |
dc.contributor.author | Odland, Jon Øyvind | |
dc.contributor.author | Cavanagh, Jorunn Pauline | |
dc.contributor.author | Flægstad, Trond | |
dc.contributor.author | Sovershaeva, Evgeniya | |
dc.date.accessioned | 2023-12-21T09:57:21Z | |
dc.date.available | 2023-12-21T09:57:21Z | |
dc.date.issued | 2023-10-07 | |
dc.description.abstract | Objectives: Chronic lung disease is a recognized complication in children
with HIV. Acute respiratory exacerbations (ARE) are common among this
group and cause significant morbidity. Exhaled nitric oxide (eNO) is a known
marker of local airway inflammation. We investigated the association between
eNO and ARE, biomarkers of systemic inflammation, and the effect of azithromycin on eNO levels.<p>
<p>Methods: Individuals aged 6–19 years with HIV-associated chronic lung disease in Harare, Zimbabwe, were enrolled in a placebo-controlled randomized
trial investigating the effect of 48-week azithromycin treatment on lung function and ARE. eNO levels and biomarkers were measured at inclusion and
after treatment in a consecutively enrolled subset of participants. Linear regression and generalized linear models were used to study associations between
eNO and ARE, biomarkers, and the effect of azithromycin on eNO levels.
<p>Results: In total, 172 participants were included in this sub-study, 86 from the
placebo group and 86 from the azithromycin group. Participants experiencing at least one ARE during follow-up had significantly higher eNO levels at baseline than participants who did not (geometric mean ratio 1.13, 95% confidence
interval [CI] 1.03–1.24, p = 0.015), adjusted for trial arm, age, sex and history
of tuberculosis. Matrix metalloproteinase (MMP)-3, -7, and -10 were significantly associated with higher baseline eNO levels. At 48 weeks, azithromycin
treatment did not affect eNO levels (geometric mean ratio 0.86, 95% CI 0.72–
1.03, p = 0.103).
<p>Conclusion: Higher baseline eNO levels were a risk factor for ARE. eNO was
associated with proinflammatory biomarkers previously found to contribute to
the development of chronic lung disease. The potential use of eNO as a marker
of inflammation and risk factor for ARE in HIV-associated chronic lung disease needs further investigation. | en_US |
dc.identifier.citation | Flygel, Hameiri-Bowen, Simms, Rowland-Jones, Ferrand, Bandason, Yindom, Odland, Cavanagh, Flægstad, Sovershaeva. Exhaled nitric oxide is associated with inflammatory biomarkers and risk of acute respiratory exacerbations in children with HIV-associated chronic lung disease. HIV Medicine. 2023 | en_US |
dc.identifier.cristinID | FRIDAID 2186604 | |
dc.identifier.doi | 10.1111/hiv.13565 | |
dc.identifier.issn | 1464-2662 | |
dc.identifier.issn | 1468-1293 | |
dc.identifier.uri | https://hdl.handle.net/10037/32193 | |
dc.language.iso | eng | en_US |
dc.publisher | Wiley | en_US |
dc.relation.ispartof | Flygel, T.T. (2024). HIV Infected African Children: Gut microbiota in relation to chronic lung disease and long-term antibiotic treatment. (Doctoral thesis). <a href=https://hdl.handle.net/10037/33175>https://hdl.handle.net/10037/33175</a>. | |
dc.relation.journal | HIV Medicine | |
dc.rights.accessRights | openAccess | en_US |
dc.rights.holder | Copyright 2023 The Author(s) | en_US |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | en_US |
dc.rights | Attribution 4.0 International (CC BY 4.0) | en_US |
dc.title | Exhaled nitric oxide is associated with inflammatory biomarkers and risk of acute respiratory exacerbations in children with HIV-associated chronic lung disease | en_US |
dc.type.version | publishedVersion | en_US |
dc.type | Journal article | en_US |
dc.type | Tidsskriftartikkel | en_US |
dc.type | Peer reviewed | en_US |